Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AMS vs HH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AMS Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)

AMS Overall Winner 6-Pillar Tally: AMS 5 – 0 HH (1 Tie) Matrix Metrics: AMS 7 – 3 HH

As of Nov 16, 2026, American Shared Hospital Services (AMS) is the stronger overall head-to-head candidate over HH (HH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AMS carries a Unified Composite Score of 33.8/100 (SELL) at $1.07 (44.6x Forward P/E, -7.4% operating margin), whereas HH carries 54.7/100 (HOLD) at $24.97 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While HH currently prints a higher short-term Unified Composite Score (54.7/100 HOLD vs. AMS 33.8/100 SELL), AMS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-7.4% vs. N/A operating margin) and revenue trajectory (+19.2% vs. N/A YoY).
  • Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile HH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AMS vs HH
AMS NYSE American Head-to-Head Winner
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap $7.2M
TTM Revenue $30M
Forward P/E 44.6x
Beta / 30D Vol 0.18β · 46% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 24.0 Fund 38.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 27
RSI-14: 27.1 · SMA20: $1.21 · SMA50: $1.32
HH US Equity
HH
Institutional Equity
$24.97
-0.1% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
54.7 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (AMS 5 – 0 HH)

Columns: Metric · AMS · HH
1. Valuation Multiples AMS
Forward P/E 44.6x N/M
Trailing P/E 44.6x N/M
PEG Ratio N/M N/M
EV / Revenue 0.8x N/M
2. Growth & Scale AMS
Revenue Growth (YoY) +19.2% N/A
Earnings Growth (YoY) -38.1% N/A
TTM Revenue (USD) $30M N/A
Market Cap $7.2M N/A
3. Profitability & Quality AMS
Gross Margin 34.8% N/A
Operating Margin -7.4% N/A
Net Profit Margin -5.8% N/A
Return on Equity (ROE) -12.1% N/A
4. Balance Sheet & Cash Flow AMS
Cash Generation (TTM) -$916,000 N/A
Cash Flow Margin -3.0% N/A
Net Cash / Leverage $17M Net Debt (0.95x D/E) N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat AMS
OpEx & R&D Intensity 42.2% of Rev ($13M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AMS (7) vs HH (3)
Institutional Metric AMS HH Criterion Row Edge
Market Capitalization
Scale
$7.2M N/A Larger Scale AMS
Trailing P/E Ratio
Valuation
44.6x N/M Lower Multiple AMS
Forward P/E Ratio
Valuation
44.6x N/M Lower Multiple AMS
Revenue Growth (YoY)
Growth
+19.2% N/A Higher Growth AMS
Operating Margin (TTM)
Profitability
-7.4% N/A Higher Margin AMS
Net Profit Margin
Profitability
-5.8% N/A Higher Margin AMS
Return on Equity (ROE)
Capital Efficiency
-12.1% N/A Higher ROE AMS
52-Week Range Position
Momentum
6% ($1–$2) 45% ($25–$25) Stronger Trend HH
Beta / 30D Volatility
Risk Regime
0.18β · 46% Vol N/A Lower Realized Risk HH
Unified Institutional Score
Composite Signal
33.8 / 100 (SELL) 54.7 / 100 (HOLD) Higher Composite HH
Trailing 12M Revenue (USD)
Operating Scale
$30M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$916,000 ($17M Net Debt (0.95x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HH +16.31 pp
AMS: -16.41% · HH: -0.1%
3M Horizon HH +16.31 pp
AMS: -16.41% · HH: -0.1%
6M Horizon HH +16.31 pp
AMS: -16.41% · HH: -0.1%
1Y Horizon HH +16.31 pp
AMS: -16.41% · HH: -0.1%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AMS vs HH. Trailing 12-month operating profitability (AMS -7.4% vs HH N/A) and valuation multiples (AMS 44.6x vs HH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AMS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$30M
Gross Margin34.8%
Op. Margin-7.4%
ROE / Fwd P/E-12.1% · 44.6x
HH ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AMS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AMS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $7.2M market capitalization and -7.4% operating margin.
OpEx & R&D Reinvestment 42.2% of Rev ($13M)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (18 partners):
Taiwan Semiconductor Manufacturing Company GlobalFoundries ASE Technology Holding Amkor Technology
HH Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AMS vs HH Key Questions & Quantitative Answers

As of Nov 16, 2026, American Shared Hospital Services (AMS) is the stronger overall head-to-head candidate over HH (HH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AMS carries a Unified Composite Score of 33.8/100 (SELL) at $1.07 (44.6x Forward P/E, -7.4% operating margin), whereas HH carries 54.7/100 (HOLD) at $24.97 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While HH currently prints a higher short-term Unified Composite Score (54.7/100 HOLD vs. AMS 33.8/100 SELL), AMS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-7.4% vs. N/A operating margin) and revenue trajectory (+19.2% vs. N/A YoY). Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile HH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AMS leads the Growth & Scale pillar: AMS posts +19.2% YoY revenue growth and -38.1% YoY earnings growth on $30M TTM revenue (34.8% gross margin, -7.4% operating margin), compared with HH at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, AMS generates $30M in USD-normalized revenue versus N/A for HH. In operating R&D and SG&A reinvestment, AMS deploys 42.2% of Rev ($13M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for HH.

AMS screens cheaper on headline valuation multiples. AMS trades at 44.6x Forward P/E, 44.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-3.0% FCF margin), whereas HH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMS (-12.1% ROE) versus HH (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, AMS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 46% Vol realized risk). By comparison, HH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.